Deb S, Sohanpal S K, Soni R, Lenôtre L, Unwin G
Division of Neuroscience, University of Birmingham, Birmingham, UK.
J Intellect Disabil Res. 2007 Oct;51(Pt 10):766-77. doi: 10.1111/j.1365-2788.2007.00950.x.
Psychopharmacological intervention in the management of behaviour problems in adults with intellectual disabilities (ID) has become a common treatment strategy. This has become a cause for concern, given that the evidence for its effectiveness is uncertain and most drugs are not licensed for this use.
A comprehensive systematic review of empirical research on the effectiveness of antipsychotic medication was conducted. Electronic and manual searches of literature were conducted. Stringent scientific methodology determined those primary trials that were worthy of inclusion.
This review revealed one randomized controlled trial (RCT), one controlled, four uncontrolled prospective and three retrospective case series studies in adults. Additionally, two studies in both adults and children--one crossover RCT and one prospective controlled trial--were found.
Presently, there is RCT-based evidence for risperidone to be effective in both adults and children; however, this treatment carries a certain amount of risk associated with adverse effects. There is also evidence to support the use of other antipsychotics, primarily atypicals, but the evidence is based on noncontrolled case studies. There is currently not enough evidence available to recommend specific medication for specific behaviour problems. Before prescribing medication, clinicians should carry out a thorough assessment of behaviour, including its causes and consequences, and draw up a formulation providing the rationale for the prescribed intervention after considering all medication- and nonmedication-based management options.
对成年智障人士行为问题进行精神药理学干预已成为一种常见的治疗策略。鉴于其有效性证据并不确定且大多数药物未获此用途许可,这已引发担忧。
对关于抗精神病药物有效性的实证研究进行了全面的系统评价。通过电子和人工检索文献。严格的科学方法确定了那些值得纳入的主要试验。
该评价揭示了一项针对成年人的随机对照试验(RCT)、一项对照试验、四项非对照前瞻性试验和三项回顾性病例系列研究。此外,还发现了两项针对成年人和儿童的研究——一项交叉RCT和一项前瞻性对照试验。
目前,有基于RCT的证据表明利培酮对成年人和儿童均有效;然而,这种治疗存在一定数量与不良反应相关的风险。也有证据支持使用其他抗精神病药物,主要是非典型药物,但证据基于非对照病例研究。目前没有足够的证据推荐针对特定行为问题的特定药物。在开药前,临床医生应全面评估行为,包括其原因和后果,并在考虑所有基于药物和非药物的管理选项后制定一份说明所开干预措施理由的方案。